Neuroscience

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL),...

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of...

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew...

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Quantitative biomarkers of demyelination can improve clinical trial design and accelerate development of disease-modifying therapeutics SAN FRANCISCO, July 14, 2022...

error: Content is protected !!